CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 877 enrolled
Drug / intervention
RT-PCR Test +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05614011
NCT05614011N/ACompleted

Q-POC SARS-CoV-2 Assay (Q27001) Clinical Performance Study Plan

QuantuMDx Group Ltd·interventional·Posted Nov 14, 2022·Updated Feb 28, 2024

In Brief

A clinical study evaluating RT-PCR Test and Real-time PCR Test for COVID-19. Completed, enrolled 877 participants across 3 sites.

Detailed Summary

Q-POC SARS-CoV-2 moderate complexity PCR test performance evaluation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States

Timeline

N/ACompletedFinished
2023202420252026
First PostedNov 14, 2022
Enrollment StartNov 28, 2022
Primary CompletionMay 17, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.6 years ago

Interventions

RT-PCR Testother

High sensitivity RT-PCR COVID-19 Test. A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's Instructions For Use (IFU) in one nostril.

Real-time PCR Testother

Mid-turbinate nasal swab samples will be taken from the opposite nostril that was not swabbed for the comparator sample using Copan FLOQ swabs and placed into MSwab buffer. In instances where opposite nostrils cannot be swabbed for both the comparator and the candidate tests, a 15-minute waiting period to allow for viral reloading will occur before collecting the candidate test sample.